Compare IGIC & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IGIC | YDES |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | Jordan | Taiwan |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.2M |
| IPO Year | N/A | N/A |
| Metric | IGIC | YDES |
|---|---|---|
| Price | $23.82 | $11.36 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $30.33 | N/A |
| AVG Volume (30 Days) | ★ 58.8K | 57.9K |
| Earning Date | 02-24-2026 | 09-30-2025 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $525,808,999.00 | $510,360.00 |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $3.05 | N/A |
| P/E Ratio | $8.45 | ★ N/A |
| Revenue Growth | N/A | ★ 45.76 |
| 52 Week Low | $20.82 | $5.30 |
| 52 Week High | $27.76 | $31.00 |
| Indicator | IGIC | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | N/A |
| Support Level | $23.36 | N/A |
| Resistance Level | $24.37 | N/A |
| Average True Range (ATR) | 0.63 | 0.00 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 25.54 | 0.00 |
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.